SDS Optic
First ever European based cutting-edge medical DeepTech connecting molecular biology with novel photonics technologies, chemistry & biomedical engineering.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | €3.0m | Post IPO Equity | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1557 % | 100 % | (65 %) | (3 %) | (73 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (110 %) | 7 % | 10 % | 11 % | (23 %) | (369 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (292 %) | - | - | - | (47 %) | (464 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
SDS Optic is a pioneering startup specializing in advanced medical diagnostics. The company has developed a cutting-edge technology called inPROBE, which focuses on the rapid and highly accurate detection of substances in the body, such as cancer markers. This technology leverages laser beams and innovative components to identify and measure these substances with exceptional precision. The results are then processed through a specialized algorithm, converting the data into numerical values that indicate the levels of the tested compounds, such as the HER2 cancer marker.
SDS Optic primarily serves healthcare providers, including hospitals, clinics, and research institutions, who require precise and quick diagnostic tools to improve patient outcomes. The company operates in the medical diagnostics market, which is a rapidly growing sector driven by the increasing demand for early and accurate disease detection.
The business model of SDS Optic revolves around the development, production, and sale of its inPROBE technology. The company generates revenue by selling these diagnostic devices to healthcare providers and possibly through licensing agreements with other medical technology firms. Additionally, SDS Optic may offer maintenance and support services for its products, providing an ongoing revenue stream.
In summary, SDS Optic is at the forefront of medical diagnostics innovation, offering a highly sensitive and rapid detection technology that can significantly enhance the accuracy of disease markers identification. This positions the company as a valuable player in the healthcare industry, catering to the needs of medical professionals and institutions seeking reliable diagnostic solutions.
Keywords: medical diagnostics, cancer markers, inPROBE technology, laser beams, healthcare providers, precision detection, HER2 marker, innovative components, healthcare market, revenue model.